Sargramostim
- Generic Name
- Sargramostim
- Brand Names
- Leukine
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 123774-72-1
- Unique Ingredient Identifier
- 5TAA004E22
- Background
Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.
- Indication
For the treatment of cancer and bone marrow transplant
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Hematopoietic Subsyndrome of Acute Radiation Syndrome, Hodgkin's Lymphoma, Neutropenia, Non-Hodgkin's Lymphoma (NHL), Severe Infection
- Associated Therapies
- Allogenic bone marrow transplantation therapy, Autologous bone marrow transplantation therapy, Autologous peripheral haematopoietic stem cell transplant
Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board
Climb Bio, Inc. appoints Douglas E. Williams, Ph.D., as Chair of its Board of Directors, succeeding Andrew Levin, who remains a director. Williams brings over 30 years of biotech leadership experience, including roles at Sana Biotechnology, Codiak BioSciences, and Biogen. He will guide Climb Bio's mission to develop treatments for immune-mediated diseases, focusing on the company's lead product, budoprutug.
How rheumatoid arthritis and Down syndrome are helping researchers find treatments for Alzheimer's
Huntington Potter's clinical trial tests Leukine for reversing Alzheimer's memory loss. Alzheimer's affects 10% of those over 65 and 30-40% of those over 85. Leukine, an FDA-approved drug, showed improvement in a 3-week trial and is now in a 24-week trial. Alzheimer's and Down syndrome share a connection through chromosome 21, influencing Alzheimer's research. Current Alzheimer's drugs slow decline, not reverse it, with side effects like brain bleeding. Behavioral changes like exercise and diet can reduce Alzheimer's risk.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath